You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药称52万人次接种新型肺炎疫苗未见严重不良反应
阿思达克 04-22 09:26
国药集团中国生物昨日(21日)披露其新冠疫苗大规模紧急使用的安全性数据,经过对紧急使用的近52万人次(截至去年12月1日)的数据进行分析,集团称大规模新型冠病毒灭活疫苗(Vero细胞)进行紧急使用後,一般反应的发生率较低,未见严重不良反应,疫苗具有良好的安全性。

中国核心学术期刊《中华流行病学杂志》刊登题为《新型冠状病毒灭活疫苗(Vero细胞)大规模紧急使用安全性评价》的论文,发布基於国药集团中国生物北京制品研究所、武汉生物制品研究所的新型冠状病毒灭活疫苗大规模紧急使用安全性评价。研究是基於其自主开发的疫苗接种讯息采集系统所收集的数据。(ek/u)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account